Back to Search
Start Over
Aiming for the cure in myeloma: Putting our best foot forward.
- Source :
- Blood Reviews; Nov2023, Vol. 62, pN.PAG-N.PAG, 1p
- Publication Year :
- 2023
-
Abstract
- Frontline therapy for multiple myeloma (MM) is evolving to include novel combinations that can achieve unprecedented deep response rates. Several treatment strategies exist, varying in induction regimen composition, use of transplant and or consolidation and maintenance. In this sea of different treatment permutations, the overarching theme is the powerful prognostic factors of disease risk and achievement of minimal residual disease (MRD) negativity. MM has significant inter-patient variability that requires treatment to be individualized. Risk-adapted and response-adapted strategies which are increasingly being explored to define the extent and duration of therapy, and eventually aim for functional curability. In addition, with T-cell redirection therapies rapidly revolutionizing myeloma treatments, the current standard of care for myeloma will change. This review analyzes the current relevant literature in upfront therapy for fit myeloma patients and provides suggestions for treatment approach while novel clinical trials are maturing. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 0268960X
- Volume :
- 62
- Database :
- Supplemental Index
- Journal :
- Blood Reviews
- Publication Type :
- Academic Journal
- Accession number :
- 173969499
- Full Text :
- https://doi.org/10.1016/j.blre.2023.101116